Drug Trial Radar · NCT00804284
Database Surveillance Safety Study of PENTACEL® Vaccine
Last checked: Nov 19, 2026Latest source record: Aug 19, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62,538
Actual
Start
Sep 2008
Primary completion
Aug 2014
Study completion Jan 2015
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 8, 2008
Design
- Study type
- Observational
- Who can join
- Male only, from 6 weeks, up to 24 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective for this study is to characterize the safety profile of PENTACEL® vaccine for identification of potential vaccine-related adverse events not currently associated with PENTACEL® vaccine administration.
Conditions
- Diphtheria
- Tetanus
- Pertussis
- Haemophilus Influenzae
Interventions
DTaP-IPV/HibBiological
0.5 mL, Intramuscular
Other DTap VaccinesBiological
0.5 mL, Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- A summary of all non-elective hospitalization and emergency room visits as well as outcome of interest from chart review.Time frame: Up to 6 months post -dose 4 DTap Vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Oakland, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.